Literature DB >> 30742035

Treatment timing well tolerated in bladder cancer.

Louise Stone1.   

Abstract

Entities:  

Year:  2019        PMID： 30742035     DOI： 10.1038/s41585-019-0162-x

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma.

Authors:  Nora Sundahl; Gillian Vandekerkhove; Karel Decaestecker; Annabel Meireson; Pieter De Visschere; Valérie Fonteyne; Daan De Maeseneer; Dries Reynders; Els Goetghebeur; Jo Van Dorpe; Sofie Verbeke; Matti Annala; Lieve Brochez; Kim Van der Eecken; Alexander W Wyatt; Sylvie Rottey; Piet Ost
Journal:  Eur Urol       Date:  2019-01-19       Impact factor: 20.096
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.